Janux Therapeutics, Inc. (JANX) has disclosed a new risk, in the Capital Markets category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Janux Therapeutics, Inc. faces significant risks due to international trade policies, including tariffs, sanctions, and trade barriers, which could adversely impact its business operations and financial condition. The company’s reliance on third-party suppliers, particularly those located outside the United States like WuXi Biologics in China, exposes it to potential disruptions and increased costs due to changing trade regulations and tariffs. These developments may lead to higher research and development expenses, supply chain complexities, and delays in clinical trials, placing Janux at a competitive disadvantage. Additionally, geopolitical tensions and trade disputes could further exacerbate these challenges, affecting investor confidence and the company’s ability to secure financing, ultimately hindering its growth prospects.
The average JANX stock price target is $75.13, implying 189.30% upside potential.
To learn more about Janux Therapeutics, Inc.’s risk factors, click here.